The coming weeks represent a pivotal period for Bath & Body Works. As the company gears up to report its quarterly earnings on February 19, a combination of legal pressures and a significant strategic pivot is weighing on investor sentiment. The central question is whether management’s renewed focus on core operations and a substantial cost-cutting initiative can steer the business toward a recovery.
Earnings Report to Gauge Turnaround Progress
All eyes will be on the leadership team, headed by CEO Daniel Heaf, when fourth-quarter 2025 results are disclosed after the U.S. market closes on February 19. Market expectations are subdued. The earnings forecast calls for at least $1.70 per share, a figure that sits notably below the prior year’s result of $2.09 per share.
Analysts will scrutinize this report for two key indicators: signs of margin stabilization and tangible progress on the $250 million cost-reduction program. Investors are also looking ahead to a potential growth catalyst: the planned expansion onto the Amazon marketplace in 2026. This move is intended to access new customer segments and diversify the company’s sales channels.
Legal Deadline Looms Over Growth Claims
Adding to the near-term pressure is an impending legal deadline. Several U.S. law firms have set March 16 as the cutoff for investors to seek lead plaintiff status in a securities class action lawsuit. The suit alleges that Bath & Body Works issued misleading statements regarding its growth strategy between June 2024 and November 2025.
Should investors sell immediately? Or is it worth buying Bath & Body Works?
The litigation centers on the company’s expansion into new product categories, specifically hair care and laundry. According to the filing, these segments failed to deliver the projected sales growth. The complaint further accuses management of obscuring underlying financial weakness through brand collaborations, actions that preceded the necessary downward revision of the annual forecast in August 2025.
Strategic Retreat and Investor Skepticism
In response to these challenges, Bath & Body Works has already initiated a strategic pullback, exiting the hair care and men’s grooming categories. The focus is now squarely redirected to its core fragrance and body care business. While executives have framed 2026 as an investment year, anticipating a recovery in the latter half, some institutional investors remain unconvinced.
Recent regulatory filings underscore this skepticism, revealing a retreat by notable shareholders. For instance, Graphene Investments divested its entire position of approximately 114,700 shares in late January. The upcoming fourth-quarter earnings release now serves as a critical test for this refined strategy. The figures will reveal whether cost-saving measures are taking hold or if operational headwinds, compounded by legal uncertainties, continue to dominate.
Ad
Bath & Body Works Stock: Buy or Sell?! New Bath & Body Works Analysis from February 6 delivers the answer:
The latest Bath & Body Works figures speak for themselves: Urgent action needed for Bath & Body Works investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 6.
Bath & Body Works: Buy or sell? Read more here...
